Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine)
- Region
- 🇪🇺 EU
- Active substance
- meningococcal groups A, C, W-135 and Y conjugate vaccine
- Company
- Pfizer Europe MA EEIG
- Status
- Authorised
- Therapeutic area
- Meningitis, Meningococcal
- CHMP opinion
- Thu 16 Feb 2012
- EU approval
- Fri 20 Apr 2012
- Application
- EMEA/H/C/002226
- ATC
- J07AH08
- Official record
- www.ema.europa.eu
Indication
Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Penbraya Withdrawn · Pfizer Europe MA EEIG
Follow Nimenrix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.